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The Mexican gray wolf (Canis lupus baileyi) is a federally 
protected endangered carnivore listed under the Endangered 
Species Act since 1976, when the species was nearly extinct.5 
Between 1977 and 1980, the Mexican Wolf Species Survival 
Plan (MWSSP) established a breeding population, which in 
2014 numbered 248 animals distributed among 55 facilities.5 
Because of captive-breeding and reintroduction, as per the 
U.S. Fish & Wildlife Service Ecological Services of the 
Southwest Region (https://www.fws.gov/southwest/es/mexi-
canwolf/reintroproj.html), by the end of 2016, there were 
113 wolves distributed among 23 packs in the wild.
In December 2014, a captive-born 12-y-old intact male 
Mexican gray wolf, housed at a facility involved in the 
MWSSP, was presented to staff veterinarians because of 
inappetence and weight loss of 5.5 kg over the course of 15 
mo. Abdominal radiographs were unrewarding. The animal 
was sedated for abdominal ultrasonography, which revealed 
a thickened duodenum and peritoneal effusion. An explor-
atory celiotomy allowed detection and repair of 2 duodenal 
perforations. Persisting clinical signs led to a second celiot-
omy that revealed a 4-cm mesenteric mass, which was diag-
nosed histologically as a suspected neuroendocrine 
carcinoma. Over the next 16 mo, the wolf was maintained on 
famotidine and omeprazole, and inconsistently received 
sucralfate, pantoprazole (Protonix, Pfizer, Philadelphia, PA), 
and maropitant (Cerenia, Zoetis, Kalamazoo, MI). During 
this time, the animal was intermittently anorexic and would 
chronically lick his lips causing caretakers to suspect nausea 
and acid reflux. Progressive anorexia, suspected chronic acid 
reflux, and lethargy prompted euthanasia.
At autopsy, the animal had moderate generalized muscle 
atrophy, scant-to-moderate adipose stores, and was dehy-
drated. There was multisegmental chronic-active ulcerative 
esophagitis. The abdominal cavity contained 200 mL of 
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Gastrinoma and Zollinger–Ellison syndrome 
in canids: a literature review and a case in a 
Mexican gray wolf
Jason D. Struthers,1 Nick Robl, Valerie M. Wong, Matti Kiupel
Abstract. Gastrinoma, an infrequent diagnosis in middle-aged dogs, occurs with nonspecific gastrointestinal 
morbidity. Laboratory tests can yield a presumptive diagnosis, but definitive diagnosis depends on histopathology and 
immunohistochemistry. We describe a malignant pancreatic gastrinoma with lymph node metastases and corresponding 
Zollinger–Ellison syndrome in a Mexican gray wolf (Canis lupus baileyi) and review this endocrine neoplasm in domestic 
dogs. A 12-y-old, captive, male Mexican gray wolf developed inappetence and weight loss. Abdominal ultrasonography 
revealed a thickened duodenum and peritoneal effusion. Two duodenal perforations were noted on exploratory celiotomy 
and were repaired. Persisting clinical signs led to a second celiotomy that revealed a mesenteric mass, which was diagnosed 
histologically as a neuroendocrine carcinoma. During the following 16 mo, the wolf received a combination of H
2
-receptor 
antagonists, proton-pump inhibitors, gastroprotectants, and anti-emetics, but had recurrent episodes of anorexia, nausea, acid 
reflux, and remained underweight. Worsening clinical signs and weakness prompted euthanasia. The antemortem serum 
gastrin concentration of 414 ng/L (reference interval: 10–40 ng/L) corroborated hypergastrinemia. Autopsy revealed a mass 
expanding the right pancreatic limb; 3 parapancreatic mesenteric masses; duodenal ulcers; focal duodenal perforation with 
septic fibrinosuppurative peritonitis; chronic-active ulcerative esophagitis; and poor body condition. The pancreatic mass 
was diagnosed histologically as a neuroendocrine carcinoma and the parapancreatic masses as lymph node metastases. 
Immunohistochemistry of the pancreatic mass was positive for gastrin and negative for glucagon, insulin, pancreatic 
polypeptide, serotonin, somatostatin, and vasoactive intestinal peptide.
Key words: Canis lupus baileyi; dogs; gastrin; gastrinoma; Mexican gray wolf; neuroendocrine tumor; ulcer; Zollinger–
Ellison syndrome.
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dark-brown fluid, and peritoneal surfaces were roughened 
with fibrin and reactive fibrovascular tissue consistent with 
peritonitis. Segmentally, the duodenum and the proximal 
jejunum were uniformly dilated up to 6 cm in circumference, 
and 13 cm distal to the pylorus, on the antimesenteric border, 
the duodenum was focally perforated. The serosal defect was 
stained with bile, and covered by fibrin, edema, and hemor-
rhage. The duodenal mucosa, extending for 25 cm, had mul-
tifocal, <0.5 cm diameter ulcers. The lumen contained 
bile-stained digesta and blood clots. Focally expanding the 
right pancreatic limb, 6 cm from the right and left pancreatic 
junction, was a 3.5 × 3 × 2 cm firm mass that was moderately 
well demarcated and mottled white-to-gray to dark-red on 
cross-section (Fig. 1). Within the mesentery adjacent to the 
pancreatic limbs, there were 3 firm masses, which measured 
2.5 cm3, 7.5 × 3.5 × 2.5 cm, and 4.5 × 3 × 2.5 cm (Fig. 1). On 
cross-section, all masses were similar to the pancreatic mass.
Additional findings included moderate leptomeningeal 
fibrosis, splenic contraction, focal adrenal gland cortical 
nodular hyperplasia, hepatic nodular hyperplasia with gly-
cogen-type vacuolation, and gastric mucosal hyperplasia 
(Fig. 2). The pancreatic mass and the mesenteric masses 
were histologically similar. Adjacent to the opening of the 
common bile duct was a highly cellular and infiltrative mul-
tilobular neuroendocrine neoplasm dissected by thick 
fibrous connective tissue (Fig. 3). The mass disrupted and 
replaced pancreatic acini, parapancreatic adipose tissue, and 
the duodenal serosa and muscularis externa. Neoplastic 
cells were arranged in packets and rosettes separated by thin 
fibrovascular tissue. The cells had poorly defined borders, 
eosinophilic loosely granular cytoplasm, and round-to-
ovoid to notched nuclei with coarse chromatin. The mitotic 
count was 3 per ten 400× high-power fields. There was 
infrequent karyomegaly. In the adjacent stroma, there was 
chronic hemorrhage. The mesenteric masses contained sim-
ilar neoplastic cells with necrosis, and the masses replaced 
and compressed residual lymphoid tissue, indicating that 
these masses were lymph node metastases. Rare clusters of 
similar neoplastic cells occupied hepatic sinusoids.
Immunohistochemistry for gastrin, glucagon, insulin, 
pancreatic polypeptide, serotonin, somatostatin, and vasoac-
tive intestinal peptide was performed on the pancreatic mass 
as described previously.4,17 The mass was negative for all 
hormones except for strong multifocal cytoplasmic gastrin 
Figures 1–4. Pancreatic gastrinoma and Zollinger–Ellison syndrome in a Mexican gray wolf (Canis lupus baileyi).
Figure 1. Focally expanding the right pancreatic limb and abutting the duodenum is a gastrinoma (*). In the adjacent mesentery, there 
are 2 lymph node metastases (x). There is a focal perforating ulcer (arrow) with bile-stained adipose tissue located 13 cm distal to the pylorus 
on the duodenal antimesenteric border. Inset: cross-section of the pancreatic gastrinoma.
Figure 2. The gastric pylorus has an undulating mucosa thickened by mucus cell hyperplasia and hypertrophy and with scattered 
lymphocytes in the lamina propria. H&E.
Figure 3. Neoplastic cells that infiltrate the pancreas are arranged in packets typical of a neuroendocrine carcinoma. H&E.
Figure 4. Neoplastic cells that infiltrate the pancreas have strong cytoplasmic staining for gastrin. Gastrin immunohistochemistry, DAB 
chromogen, hematoxylin counterstain.
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immunoreactivity (Fig. 4), which confirmed the neoplastic 
cells to be gastrin-producing.13
Gastrin concentration of 414 ng/L was determined in the 
wolf’s serum collected prior to euthanasia (125I radioimmuno-
assay; Endocrine Diagnostic Laboratory [EDL], Michigan 
State University, East Lansing, MI).16 Although a serum gas-
trin reference interval (RI) is lacking for the Mexican gray 
wolf, we presume that the levels are similar to those reported 
in dogs. In dogs, the baseline serum gastrin concentration var-
ies among reports, likely because of different assays, and is 
described as a range of 10–40 ng/L,16 66–76 pg/mL,18 23–104 
pg/mL,18 20–100 pg/mL,18 27–85 pg/mL,6 45–98 pg/mL,6 or 
as a mean of 40 pg/mL19 or 71 pg/mL.3 In the case of our 
wolf, the gastrin level was ~10 times the higher end of the 
canine RI (10–40 ng/L) used by the EDL. In dogs with gastri-
noma, serum gastrin concentrations are typically >3 times the 
upper end of the RI, but more specific values are lacking 
given the rarity of reported cases.21 The therapeutic use of 
H
2
-receptor antagonists and proton-pump inhibitors can 
falsely increase serum gastrin, but studies in healthy dogs 
have concluded that gastrin concentrations rarely exceed 3 
times the upper end of the RI (10–40 ng/L in that study); 
therefore, therapy-related fluctuations of serum gastrin are 
unlikely to be confounded with a functional gastrinoma.16
Autopsy, histopathology, immunohistochemistry, and 
serum gastrin levels in the wolf in our study confirmed a 
diagnosis of malignant pancreatic gastrinoma with metasta-
sis to regional lymph nodes, rare tumor microemboli in 
hepatic sinusoids, and secondary duodenal peptic ulcers as a 
result of Zollinger–Ellison syndrome. One ulcer was trans-
mural and had resulted in septic suppurative peritonitis. The 
clinical suspicion of chronic acid reflux was corroborated by 
the presence of chronic-active ulcerative esophagitis.
Gastrinoma is a rarely reported neuroendocrine tumor that 
is responsible for Zollinger–Ellison syndrome, which is 
characterized by gastric acid hypersecretion, upper gastroin-
testinal ulceration, and non-beta islet cell tumors.18 The syn-
drome was first described in a dog in 1976,18 and has been 
reported mostly in domestic dogs,21 a few cats,21 and now in 
a Mexican gray wolf. Affected dogs are middle-aged (range: 
3.5–12 y; mean: 8.2 y) without a breed predisposition, and 
females may be overrepresented.21 The tumor typically 
involves the pancreatic islets,14 but has also been reported in 
the duodenal wall at the level of the major duodenal papilla,20 
in the liver,13 in the mesenteric root,2 and in parapancreatic 
lymph nodes,10 sometimes without a detected pancreatic 
mass, although autopsies were not always performed. The 
predilection of this tumor for the pancreas is interesting 
given that the adult canine pancreas lacks gastrin-producing 
cells.13 However, gastrin-producing cells are present in the 
pancreas of the developing fetus and neonate, and in the 
adult duodenum and gastric antrum.13 Theories to explain 
how gastrin-producing neoplasms develop in pancreatic 
islets are multiple and include: the translocation of gastrin-
producing cells from the duodenum or gastric antrum to the 
pancreatic islets during fetal development; the differentiation 
of pluripotent cells, or nesidioblasts, within the pancreatic 
islets to gastrin-producing cells or G cells; and de-differenti-
ation from an existing islet pancreatic endocrine cell into a 
gastrin-producing cell.13 Gastrinoma tumor cells are reported 
to have cytoplasmic granules characteristic of those in delta 
cells.1
Patients with functional gastrinomas develop hypergas-
trinemia that results in nonspecific signs of gastrointestinal 
disease. The pathophysiology involved is a perturbed gastric 
pH regulatory feedback loop. Normally, gastrin-producing 
cells or G cells of the distal part of the stomach produce con-
trolled amounts of gastrin that are essential for gastrointesti-
nal system function.12 The anticipation of eating or gastric 
distension or an ingested meal (e.g., protein or high stomach 
pH) leads to gastrin release into the blood stream, which 
stimulates parietal cells to increase gastric acid production, 
thus causing a decrease of gastric pH.12,18 To avoid gastric 
hyperacidity, G cells closely monitor the pH of the distal part 
of the stomach, and once the pH reaches a critical point (pH 
of 1–2),12 the release of gastrin is inhibited. Consequently, 
the stimulus to produce gastric acid is removed, and the 
stomach pH stabilizes.12 This gastrin-stomach pH regulatory 
feedback loop is a major mechanism that protects against 
acid-induced mucosal damage. In instances of abnormal and 
uncontrolled hypergastrinemia, such as occurs with a func-
tional gastrinoma, the regulatory feedback loop is perturbed 
and rendered ineffective at stabilizing stomach pH. There-
fore, highly acidic stomach contents may empty into the duo-
denum or may be expelled through the esophagus. Duodenal 
acidification likely activates a second protective mechanism, 
the intestinal negative feedback loop, which relies on neuro-
nal reflexes and secretin to suppress gastric acid production 
and delay gastric emptying.12 The sequelae of hypergastrin-
emia are gastric acid hypersecretion and gastric mucosal 
hyperplasia.18,21
Common clinical signs are vomiting, weight loss, depres-
sion, lethargy, anorexia, and diarrhea;21 in those patients with 
gastrointestinal ulceration, which is the majority,21 there may 
be hematemesis, melena, hematochezia, abdominal pain, 
anemia, fever, leukocytosis, elevated urea, hypoalbumin-
emia, polydipsia, and electrolyte abnormalities.8–10,15,18 Other 
patients, including the wolf in our study, may develop ulcer-
ative esophagitis related to acid reflux favored by a delay in 
gastric emptying and chronic regurgitation.8,18,19,21 Less 
often, patients have steatorrhea18 or extraluminal bile duct 
obstruction.20 Because of the frequency of gastrointestinal 
ulceration, perforation and peritonitis are common.21
Diagnosing gastrinoma in a patient is complicated by 
nonspecific clinical findings, the rarity of the tumor, the 
small size of the tumor, and the variable usefulness of imag-
ing and endoscopy. The clinical signs, physical exam, and 
the minimum database (complete blood count, biochemistry) 
may suggest gastrointestinal disease, but even so, the differ-
ential diagnosis remains broad.9 Abdominal radiographs are 
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usually unremarkable unless there is perforation.10,15 Con-
trast-enhanced radiographs may show gastric wall thicken-
ing, complete pyloric obstruction, gastroduodenal ulceration, 
or increased small bowel transit time.21 Abdominal ultraso-
nography may identify a pancreatic mass or metastases,1 but 
more often it is unrewarding given the usual small tumor 
size.9,10,15 More advanced imaging modalities, such as com-
puted tomography, will increase sensitivity and may visual-
ize neoplastic masses that will require further investigation.21
Endoscopy, with endoscopic biopsies, is commonly used 
and can detect pyloric antrum hypertrophy, pyloric stenosis, 
gastrointestinal ulceration, hemorrhage, and inflammation. 
This approach is unlikely to diagnose gastrinoma and may 
result in an erroneous diagnosis of inflammatory bowel 
disease.6,10,11,15 In at least 3 cases, endoscopic biopsies revealed 
ulcerative inflammation followed by an exploratory celiotomy 
that detected a pancreatic gastrinoma,8 a pancreatic gastri-
noma with hepatic metastasis,19 or a metastatic gastrinoma.10
Although celiotomy is an invasive procedure, exploratory 
celiotomy for biopsy collection and immunohistochemistry 
may be the best diagnostic approach. This approach was used 
successfully in at least 9 cases.1,7,8,10,13,20 Other useful labora-
tory tests include a measure of basal gastric acid secretion, a 
measure of serum gastrin concentration, and provocative 
testing of gastrin secretion with intravenous secretin or cal-
cium gluconate.9,21 Provocative testing is particularly useful 
in cases of suspected gastrinoma in which serum gastrin lev-
els are normal-to-borderline.10,15
Although such laboratory tests may aid in diagnosis, in 
addition to documenting hypergastrinemia, a definitive diag-
nosis of gastrinoma is based on histologic evidence of a pan-
creatic islet cell tumor with neoplastic cells immunoreactive 
for gastrin.21 Hypergastrinemia alone is insufficient to diag-
nose a gastrinoma, because elevated basal serum gastrin may 
accompany renal failure, gastric outflow obstruction, hypo-
chlorhydria, atrophic gastritis, small intestinal resection, gas-
tric dilation and volvulus, chronic gastritis, liver disease, 
immunoproliferative enteropathy of Basenji dogs, and cer-
tain therapeutic drugs.15,21 Although immunohistochemistry 
or radioimmunoassay of tumor tissue extracts can confirm 
the presence of gastrin in the tumors, it fails to show that the 
hormone is being secreted in excess into the circulation.21 
Compatible clinical signs and lesions can correlate with a 
functional gastrinoma, but documenting concomitant hyper-
gastrinemia is more convincing.
Treatment of canine gastrinoma is difficult and palliative, 
and clinicians resort to a combination of surgical interven-
tion and long-term medical therapy.15 Early surgical inter-
vention has the advantage of making a final diagnosis and 
beginning treatment, but because of the likelihood that surgi-
cal resection will be incomplete, medical management is 
important and depends on drugs that reduce gastric acid 
secretion and treat gastrointestinal ulceration, while correct-
ing fluid and electrolyte losses.21 Proton-pump inhibitors 
such as omeprazole, alone or in combination, appear to be a 
good choice for medical management.2,14
Following a diagnosis of gastrinoma, canine patients 
have a guarded-to-poor prognosis, in part because metas-
tasis to the liver and regional lymph nodes has already 
occurred in 85% of cases.10,18,21 Canine patients receiving 
combined treatment are reported to survive up to 18 mo,21 
although 1 patient treated indefinitely with omeprazole 
was asymptomatic and survived for at least 24 mo,2 and 
another receiving ranitidine, omeprazole, and sucralfate 
survived for 26 mo.14 Patients were often euthanized upon 
diagnosis or following the recurrence of treated disease, 
some died before a diagnosis was made,11 and others died 
from complications of the disease, including septic perito-
nitis from intestinal perforation.6,18
The disease progression of the wolf in our study mir-
rored what is described in domestic dogs diagnosed with 
gastrinoma. The wolf had nonspecific clinical signs, and 
initial bloodwork and imaging suggested gastrointestinal 
disease. Two exploratory celiotomies followed, which 
revealed duodenal ulcers and a mesenteric mass suspicious 
of a neuroendocrine carcinoma. The animal was medically 
managed until it was euthanized because of declining 
health. Autopsy and ancillary testing resulted in a definitive 
diagnosis of malignant gastrinoma, which had caused long-
standing morbidity that included multiple duodenal ulcers, 
2 instances of duodenal perforation, gastric mucosal hyper-
plasia, and reflux esophagitis. It is believed that the primary 
gastrinoma was the focal mass in the right pancreatic limb 
adjacent to the common bile duct. This location appears to 
be a frequent site in dogs,21 and its proximity to the opening 
of the bile duct favors one of the elaborated theories of the 
origin of pancreatic gastrinomas within the “gastrinoma tri-
angle”.13 This area is delimited by the common and cystic 
bile ducts superiorly, the junction of the body and the tail of 
the pancreas medially, and the junction of the second and 
third segments of the duodenum inferiorly.13 In humans, the 
development of gastrin-producing tumors in this area is 
thought to originate, in part, from ectopic gastrin-produc-
ing cells.13
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